New cast for a new era: preclinical cancer drug development revisited.
about
GEMMs as preclinical models for testing pancreatic cancer therapiesContemporary murine models in preclinical astrocytoma drug developmentXRP44X, an Inhibitor of Ras/Erk Activation of the Transcription Factor Elk3, Inhibits Tumour Growth and Metastasis in MiceStromal Hedgehog signalling is downregulated in colon cancer and its restoration restrains tumour growth.In Vitro and In Vivo Models for the Study of Human Polyomavirus InfectionSystematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsinAcidic pH-targeted chitosan capped mesoporous silica coated gold nanorods facilitate detection of pancreatic tumors via multispectral optoacoustic tomographyThe future of patient-derived tumor xenografts in cancer treatment.Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factorsDynamic treatment effect (DTE) curves reveal the mode of action for standard and experimental cancer therapiesSuccessful Xenograft of Endoscopic Ultrasound-Guided Fine-Needle Aspiration Specimen from Human Extrahepatic Cholangiocarcinoma into an Immunodeficient Mouse.Tissue-specific tumorigenesis: context matters.Three-dimensional bio-printing: A new frontier in oncology research.Noninvasive Bioluminescence Imaging of AKT Kinase Activity in Subcutaneous and Orthotopic NSCLC Xenografts: Correlation of AKT Activity with Tumor Growth Kinetics.Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.Optimization of Glioblastoma Mouse Orthotopic Xenograft Models for Translational Research.The roles of tumor- and metastasis-promoting carcinoma-associated fibroblasts in human carcinomas.Biobanking: An Important Resource for Precision Medicine in Glioblastoma.Association of Itraconazole, a Hedgehog Inhibitor, and Bladder Cancer.Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancerThe decision-making process and criteria in selecting candidate drugs for progeria clinical trials.MALDI mass spectrometry imaging of erlotinib administered in combination with bevacizumab in xenograft mice bearing B901L, EGFR-mutated NSCLC cells.When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data.The Stromal Niche for Epithelial Stem Cells: A Template for Regeneration and a Brake on Malignancy.Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.Three-dimensional tumor model mimics stromal - breast cancer cells signaling.An orthotopic mouse model of small cell lung cancer reflects the clinical course in patients.Preclinical evaluation of novel fatty acid synthase inhibitors in primary colorectal cancer cells and a patient-derived xenograft model of colorectal cancer.Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer
P2860
Q26781848-79AEDB78-7EF5-4394-9F90-3080AC53E9E8Q27026937-60B81DBC-046A-48DA-8416-0646CFC3F0FDQ27333970-CA25F4F3-20CE-402D-A179-CADCA45D41BEQ27334308-023464CA-FBF4-4C31-B3B0-575296A5C8E8Q28074684-47DCA098-4056-431E-868B-2B745732787DQ28817780-03DA04F8-D4EA-4BE9-82DC-6219F3FC872BQ30855722-E5686488-D491-49FE-B5F6-BA287D54E5E7Q33361578-110097FB-3C85-4F75-805B-6110A0FE49F0Q34537580-C2D2C6EF-5625-469B-927B-ABF30257129DQ35077800-A805215C-24AB-4DDC-8AF8-93E859207E9AQ35987437-A69594DC-E110-4C96-9BFD-23ACA82C9C7CQ36223453-E01D4860-CAF7-48DA-8344-9C56B409365CQ36296335-B23806E5-2129-4AAA-AD79-9232132DD1A0Q37642457-EBA4F372-0BA6-4510-9C9A-F1A9289245D1Q37736706-0CDFD4AA-EEFF-468D-BB95-FEAEF6589C9BQ38622790-4A8EF0D2-97F1-4CF7-B96F-2AC3690F81C1Q38694405-EC5CFE8D-B543-4CAD-9BC0-8AFC2E2B8629Q38922999-8EB6E146-DBEA-4175-85FA-99BAC38FFA3AQ39193240-1AE6628D-5204-4C33-9221-F127F7539873Q40059956-52839CF7-B10F-44D3-842C-DB0FE66D0860Q42039942-DA36C664-CD44-4DAE-B705-0EE8FE4B5B24Q42434438-6E02F408-F5B3-4F4F-AF0A-507DA9A86AA6Q47114407-B9D61B69-BE44-407D-9261-49E8E1DD474FQ47385711-7B008AA3-9E03-4386-9289-125E9C3FC4C8Q47670544-C966501B-0B43-40D1-8EE9-12795A4A6B73Q48229251-38540993-2497-4253-8D8A-E4ED9ABF7D69Q49319044-B5DDA402-2FC0-495F-8773-701E1FBC814DQ53072915-A0CD3434-B51A-4D61-9F47-4CAF7E3ED469Q55009808-A7E1A7F2-F6C3-4F8C-920C-6944C6071C73Q58699214-0F175E05-1F1A-4404-BB8D-68C78FAEB30E
P2860
New cast for a new era: preclinical cancer drug development revisited.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
New cast for a new era: preclinical cancer drug development revisited.
@en
New cast for a new era: preclinical cancer drug development revisited.
@nl
type
label
New cast for a new era: preclinical cancer drug development revisited.
@en
New cast for a new era: preclinical cancer drug development revisited.
@nl
prefLabel
New cast for a new era: preclinical cancer drug development revisited.
@en
New cast for a new era: preclinical cancer drug development revisited.
@nl
P2860
P356
P1476
New cast for a new era: preclinical cancer drug development revisited
@en
P2093
Grit S Herter-Sprie
P2860
P304
P356
10.1172/JCI68340
P407
P577
2013-09-03T00:00:00Z